Live feed09:05:00·8dPRReleasevia QuantisnowBioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026ByQuantisnow·Wall Street's wire, on your screen.BMRN· BioMarin Pharmaceutical Inc.Health Care